GET DAILY SIGNALSNatera (NTRA) Reports +34.1% Revenue Growth in Q3 2026
Key Takeaways
- Natera reported third quarter 2026 total revenue of $794.0 million, up 34.1% from $592.2 million in the prior-year period.
- The net loss narrowed to $59.9 million, or $0.42 per share, versus a loss of $87.5 million, or $0.64 per share, a year earlier.
- The company processed a record approximately 1.09 million tests, up 22.3% year over year, driven by accelerating oncology volumes.
- Management raised its full-year 2026 revenue guidance to a range of $3.005 billion to $3.035 billion.
- Signatera's average selling price (ASP, the price received per test) stepped up to roughly $1,290, from $1,271 in the prior quarter.
Why These Results Matter
Natera leads in cell-free DNA testing and precision medicine across oncology, women's health, and organ health. Its flagship Signatera test tracks molecular residual disease, or the small number of cancer cells that may remain after treatment and risk recurrence. The company has posted consistent revenue growth above 30% even while posting net losses, so each quarter tests whether heavy spending on commercial expansion and new uses is building toward sustainable, higher-margin expansion. The third quarter 2026 figures come amid expanding Medicare coverage and rising test volumes, making the report a useful checkpoint for investors assessing the path to profitability and the new long-term revenue targets.
Breaking Down the Quarter
For the third quarter ended September 30, 2026, Natera reported total revenue of $794.0 million, a 34.1% increase from $592.2 million a year earlier. The result topped consensus estimates near $705 million, thanks to higher test volumes and better average selling prices. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On the bottom line, the net loss came in at $59.9 million, or $0.42 per share, narrower than the $87.5 million, or $0.64 per share, loss from the prior-year quarter. The per-share loss missed the consensus estimate of about $0.29, reflecting continued operating investments even as revenue exceeded expectations.
Gross margin held at 64.7%, compared with 64.9% a year ago. The company processed roughly 1.09 million tests, up 22.3% from 893,600 a year earlier. Oncology tests jumped 60.9% to about 339,500, with clinical MRD volumes at approximately 316,000 and adding roughly 33,000 units from the previous quarter.
Management lifted full-year 2026 revenue guidance to $3.005 billion to $3.035 billion, up from the earlier range of $2.85 billion to $2.91 billion, and outlined a long-term target of doubling revenue to $6 billion by 2029.
Market Reaction and Sentiment
The report showed the pattern investors have seen before: solid revenue growth and higher guidance offset by a wider-than-expected loss per share. Strong volume growth and the Signatera ASP increase tend to draw positive attention, and the record test count should support that view. The raised outlook and the $6 billion goal point to confidence in ongoing demand, especially in oncology. At the same time, the earnings shortfall reflects deliberate spending on research and commercial efforts, which may limit near-term optimism among investors focused on profitability. Overall, sentiment after the report looks constructive, centered more on top-line durability than on current earnings.
What to Watch Next
After this report, several areas deserve attention as Natera moves toward its growth and profitability goals.
Guidance execution will be important. With the full-year 2026 range now at $3.005 billion to $3.035 billion, the focus turns to whether fourth-quarter volumes and ASPs can support the upper end. Continued sequential gains in clinical MRD units will serve as a key indicator of Signatera adoption.
Pricing trends also merit watching. Management has outlined a longer-term path to roughly $2,000 ASP for Signatera as coverage expands and the test enters practice guidelines. New Medicare coverage decisions and additional tumor-type approvals could act as catalysts for both volume and pricing.
Margin trends remain relevant. Revenue is expanding quickly, yet heavy investment in early cancer detection research and commercial expansion continues to pressure near-term profits. Investors will look for signs that gross margin gains and operating discipline start to reduce losses in coming quarters.
Finally, competition in liquid biopsy and genetic testing could shape sentiment as other players seek similar coverage and guideline wins. Against this backdrop, Natera's ability to turn record volumes into sustained cash flow will likely shape the next stage of its development.
Using AI Tools in My Research
When evaluating earnings momentum and post-report moves like Natera's, I find Tickeron's AI Screener helpful for scanning thousands of stocks and ETFs with filters for industry, technical patterns, fundamentals, and AI-driven signals. It surfaces ideas aligned with specific criteria more efficiently than manual reviews and supports ongoing monitoring of opportunities in the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NTRA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 02, 2026
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where NTRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 25 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 71 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.944) is normal, around the industry mean (66.911). NTRA's P/E Ratio (-289.652) is considerably lower than the industry average of (2.514). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties
Advertisement